Amgen presents late-breaking Phase 2 olpasiran data at ESC 2023

Amgen today announced data from the final analysis of the Phase 2 OCEAN(a)-DOSE study of olpasiran, a small interfering RNA (siRNA) during the Late-Breaking Science Session at the European Society of Cardiology (ESC) Annual Meeting being held in Amsterdam. In the off-treatment extension period, olpasiran showed a lasting effect on Lp(a) reduction nearly a year after the last dose.

CPAP Turns in Mixed Results for Patients With Diabetic Eye Disease

Long-term use of continuous positive airway pressure (CPAP) slowed the progression of eye disease in sleep apnea patients with non-proliferative diabetic retinopathy, a small randomized

October 7, 2023

Q&A with Obesity Society’s CEO as the field prepares for next-gen meds

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

November 2, 2024

This Biomarker Predicts Survival in Autoimmune Lung Disease

One major subgroup of patients with interstitial lung disease (ILD) arising from polymyositis/dermatomyositis (PM/DM) survived significantly longer when serum levels of interferon-λ3 were relatively low,

December 29, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.